0001144204-18-019057.txt : 20180403 0001144204-18-019057.hdr.sgml : 20180403 20180403192653 ACCESSION NUMBER: 0001144204-18-019057 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180403 DATE AS OF CHANGE: 20180403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AUBERTON-HERVE ANDRE-JACQUES CENTRAL INDEX KEY: 0001730329 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-54717 FILM NUMBER: 18735421 MAIL ADDRESS: STREET 1: 18 CHEMIN DE LA VIERGE NOIRE CITY: LA TRONCHE STATE: I0 ZIP: 38700 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bionik Laboratories Corp. CENTRAL INDEX KEY: 0001508381 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 271340346 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 483 BAY STREET STREET 2: N105 CITY: TORONTO STATE: A6 ZIP: M5G2C9 BUSINESS PHONE: 1.416.640.7887 MAIL ADDRESS: STREET 1: 483 BAY STREET STREET 2: N105 CITY: TORONTO STATE: A6 ZIP: M5G2C9 FORMER COMPANY: FORMER CONFORMED NAME: Drywave Technologies, Inc. DATE OF NAME CHANGE: 20130814 FORMER COMPANY: FORMER CONFORMED NAME: Strategic Dental Management Corp. DATE OF NAME CHANGE: 20101220 4 1 tv490253_4.xml OWNERSHIP DOCUMENT X0306 4 2018-03-31 0 0001508381 Bionik Laboratories Corp. BNKL 0001730329 AUBERTON-HERVE ANDRE-JACQUES C/O BIONIK LABORATORIES CORP. 483 BAY STREET, N105 TORONTO A6 M5G2C9 ONTARIO, CANADA 1 0 0 0 Common Stock 2018-03-31 4 C 0 12114710 0.0625 A 12679436 I Shares held through Star SCI Common Stock 2018-03-31 4 C 0 564726 0.0625 A 12679436 I Shares held through 4A Consulting and Engineering Warrant 0.0625 2017-08-14 4 A 0 1600640 0 A 2018-03-31 2022-08-14 Common Stock 1600640 1600640 I Warrants held through held through Star SCI On March 31, 2018, an aggregate amount of $821,850 in convertible promissory notes converted in accordance with their terms into (i) 12,114,710 shares of the Issuer's common stock, and (ii) 1,040,152 shares of the Issuer's common stock (the "Pending Shares") that will be issued upon the earlier of (i) a reverse stock split of the Issuers's common stock that allows for the issuance of the Pending Shares without violating the authorized share number of the Issuer and (ii) an increase in the Issuer's authorized shares of common stock. The amounts set forth in this Form 4 do not reflect the issuance of the Pending Shares, and the Reporting Person will either amend this Form 4 or file a new Form 4 reflecting the issuance. On March 31, 2018, an aggregate amount of $100,200 in convertible promissory notes converted in accordance with their terms into (i) 564,726 shares of the Issuer's common stock, and (ii) 1,039,115 shares of the Issuer's common stock (the "Pending Shares") that will be issued upon the earlier of (i) a reverse stock split of the Issuers's common stock that allows for the issuance of the Pending Shares without violating the authorized share number of the Issuer and (ii) an increase in the Issuer's authorized shares of common stock. The amounts set forth in this Form 4 do not reflect the issuance of the Pending Shares, and the Reporting Person will either amend this Form 4 or file a new Form 4 reflecting the issuance. As of the transaction date, the number of shares of common stock underlying warrants and the exercise price were not yet determinable. Such number of shares and exercise price were each determined on March 31, 2018. /s/ Andre-Jacques Auberton-Herve 2018-04-03